Aprocitentan 12.5 mg + Aprocitentan 25 mg + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Resistant Hypertension
Conditions
Resistant Hypertension
Trial Timeline
Jun 18, 2018 → Apr 25, 2022
NCT ID
NCT03541174About Aprocitentan 12.5 mg + Aprocitentan 25 mg + Placebo
Aprocitentan 12.5 mg + Aprocitentan 25 mg + Placebo is a phase 3 stage product being developed by Idorsia for Resistant Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT03541174. Target conditions include Resistant Hypertension.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03541174 | Phase 3 | Completed |
Competing Products
20 competing products in Resistant Hypertension